Active not recruitingPHASE3INTERVENTIONAL

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

At a glance

Status

Active not recruiting

Phase

PHASE3

Sponsor

Zogenix, Inc.

Enrolment target

Start

08 Mar 2022

Estimated completion

08 Nov 2027

CDKL5 Deficiency Disorder Generalized Tonic Clonic Seizure Epileptic Spasm Refractory Seizures

What is this study about?

This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

Who may be eligible?

Age 1 Year to 35 Years · Sex: ALL

Locations (46)

Ep0216 154
Birmingham, United States
Ep0216 144
Los Angeles, United States
Ep0216 101
San Francisco, United States
Ep0216 173
Aurora, United States
Ep0216 149
Washington D.C., United States
Ep0216 157
Atlanta, United States
Ep0216 113
Brookline, United States
Ep0216 134
Detroit, United States
Ep0216 166
Chapel Hill, United States
Ep0216 164
Cleveland, United States
Ep0216 120
Philadelphia, United States
Ep0216 124
Memphis, United States

+34 more sites — see the official record for the full list.

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.